Current recommendations regarding the management of blood pressure in children with chronic kidney disease are heavily based on data from a single trial, the Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of Chronic Kidney Disease in Pediatric Patients (ESCAPE) trial, with slower kidney disease progression in those with lower blood pressure targets (24 h ambulatory mean arterial pressure <50th percentile). This evidence concerns the gene ACE and kidney disorder.